Bimatoprost 0.01% or 0.03% in patients with glaucoma or ocular hypertension previously treated with latanoprost: two randomized 12-week trials

BACKGROUND: The purpose of this study was to evaluate the intraocular pressure (IOP)-lowering efficacy and safety of bimatoprost 0.01% or 0.03% as monotherapy in patients treated with latanoprost 0.005% monotherapy who require additional IOP lowering for their ocular hypertension or open-angle glauc...

Descripción completa

Detalles Bibliográficos
Autores principales: Myers, Jonathan S, Vold, Steven, Zaman, Fiaz, Williams, Julia M, Hollander, David A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2014
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971936/
https://www.ncbi.nlm.nih.gov/pubmed/24707169
http://dx.doi.org/10.2147/OPTH.S59197

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3971936/
https://www.ncbi.nlm.nih.gov/pubmed/24707169
http://dx.doi.org/10.2147/OPTH.S59197

Ejemplares similares